Industry news that matters to you.  Learn more

Archives for November 2010

Transgenomic Picks Up Clinical Data’s MDx and Biomarker Business for $15.4M

Transgenomic is buying Clinical Data’s genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 million. The transaction will allow Clinical Data to focus its resources solely on therapeutic development.

Quintiles, London Genetics Ally To Enhance Drug Discovery And Development Through Pharmacogenetics

Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

Added Complexities for Biomarkers

For metastatic colorectal cancer, there has been increasing recognition that certain molecular changes in the genes of the tumor (often called biomarkers) can help predict the benefit from certain chemotherapies like cetuximab.

One of the most frequently used biomarkers is the KRAS mutation, which predicts lack of efficacy to cetuximab and panitumumab. This has been replicated in at least a dozen large randomized studies. Several recent developments have added complexities to what had appeared to be a clear biomarker and a consistent treatment algorithm.

Rosetta, Prometheus Settle Arbitration on MicroRNA Tests

Rosetta Genomics today said that it has settled an outstanding arbitration with Prometheurs Laboratories regarding commercialization rights to Rosetta’s microRNA-based tests.

Under the terms of the settlement, Rosetta has regained US commercial rights to its miRview mets, miRview squamous, and miRview meso tests. The Rehovot, Israel-based firm will pay Prometheus $3.1 million over the next 18 months, with an initial payment of $1.2 million due on Dec. 2.

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.